Â鶹´«Ã½

• Teams share new treatments for pediatric and adult lymphoma, leukemia, myeloma 

• Topics range from exercise interventions to new CAR T and cell therapies 

• Conference happening in San Diego December 7-10  

News — BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center experts representing various specialties will highlight innovative research and advancements in hematology and hematologic cancers at the 66th annual meeting of the American Society of Hematology (ASH), to be held December 7-10 in San Diego, California. This prestigious research meeting will bring together top experts in blood disorders, providing an opportunity for Roswell Park physician-scientists to share insights into critical areas of hematology and new treatment options for hematologic cancers. 

Committed to advancing treatments for blood cancers and other hematologic conditions, Roswell Park will present breakthrough findings in areas including CAR T-cell therapy, chronic lymphocytic leukemia, and innovative immunotherapies. This year’s ASH conference offers a valuable platform for Roswell Park’s scientists and clinicians to share insights with the global hematology community. 

“The research the Roswell Park team is presenting at ASH 2024 showcases our mission to make cancer treatment more targeted and effective,” says , Senior Vice President and Associate Director for Translational Research. “By exploring new pathways and technologies, we’re working to create more personalized and impactful options for cancer patients everywhere.” 

Roswell Park-led oral abstracts 

• On Saturday, Dec. 7, at 10:45 a.m., , will present abstract 78, , in the Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina). , is senior author. 

• On Saturday, Dec. 7, at 4:45 p.m., , will present abstract 370, in the Grand Hall C (Manchester Grand Hyatt San Diego). 

• On Sunday, Dec. 8, at 10 a.m., will present abstract 525, , in the Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina). 

• On Sunday, Dec. 8, at 10:45 a.m., a study co-led by , senior author, will be presented by an expert from Weill Cornell Medicine: abstract 462, , in Ballroom 20AB (San Diego Convention Center). 

• On Sunday, Dec. 8, at 5 p.m., Janine Joseph, MS, MBA, will present abstract 705, , in San Diego Ballroom AB (Marriott Marquis San Diego Marina). , is senior author.  

• On Monday, Dec. 9, at 5:15 p.m., Taylor Mandeville, BA, will present abstract 1036, , in Room 6CF (San Diego Convention Center). is senior author.  

Posters presented by Roswell Park experts 

• On Sunday, Dec. 8, from 6 to 8 p.m., a study co-led by Dr. Cortese, senior author, will be presented by an expert from Memorial Sloan Kettering Cancer Center: abstract 3453, , in Halls G-H (San Diego Convention Center). 

• On Sunday, Dec. 8, from 6 to 8 p.m., , will present abstract 3445, , in Halls G-H (San Diego Convention Center). , is senior author. 

• On Sunday, Dec. 8, from 6 to 8 p.m., , will present abstract 3432, , in Halls G-H (San Diego Convention Center). Dr. Davila is senior author on the work. 

• On Monday, Dec. 9, from 6 to 8 p.m., , will present abstract 4392, , in Halls G-H (San Diego Convention Center). Dr. Cortese is senior author. 

• On Monday, Dec. 9, from 6 to 8 p.m., a study co-led by Dr. Hillengass, senior author, will be presented by Roswell Park resident physician Sawyer Bawek, MD, from the University at Buffalo: abstract 4658, , in Halls G-H (San Diego Convention Center). 

• On Monday, Dec. 9, Sawyer Bawek, MD, will present abstract 4236, , from 6 to 8 p.m. PST in Halls G-H (San Diego Convention Center). , Chief of Leukemia, is senior author. 

• , PharmD, is co-presenting abstract 5158, , Monday, Dec. 9, from 6 to 8 p.m., in Halls G-H (San Diego Convention Center). , is senior author and Esraa Abdalla, PharmD, a Roswell Park graduate, is first author. 

Satellite symposium 

Additionally, , Chief of Leukemia, will speak at the satellite symposium “” on Friday, Dec. 6, from 3 to 6 p.m. PST in the Seaport Ballroom ABCD, Manchester Grand Hyatt San Diego. 

These presentations showcase Roswell Park’s commitment to bridging the gap between laboratory research and clinical application, with the goal of offering patients more precise and effective treatment options. With significant progress in immunotherapies and cell-based treatments, Roswell Park’s team is positioned to make a lasting impact on the future of blood cancer therapies. 

“Our team is constantly pushing the envelope in developing next-generation therapies,” says , Deputy Director and Chair of Medicine. “The breakthroughs we’re sharing at ASH represent years of dedicated work, bringing us closer to more effective, targeted solutions that give our patients new hope and improved outcomes.” 

For more information about Roswell Park presenting doctors and ASH conference activities, please visit . 

###  

From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. Driven to eliminate cancer’s grip on humanity, the Roswell Park team of 4,000 makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Founded in 1898, Roswell Park was among the first three cancer centers nationwide to become a National Cancer Institute-designated comprehensive cancer center and is the only one to hold this designation in Upstate New York. To learn more about and the , visit , call 1-800-ROSWELL (1-800-767-9355) or email [email protected].